Creative Medical Technology Holdings Inc (CELZ) - Net Assets
Based on the latest financial reports, Creative Medical Technology Holdings Inc (CELZ) has net assets worth $6.13 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.44 Million) and total liabilities ($307.65K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Creative Medical Technology Holdings Inc's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.13 Million |
| % of Total Assets | 95.22% |
| Annual Growth Rate | 36.32% |
| 5-Year Change | -26.36% |
| 10-Year Change | N/A |
| Growth Volatility | 1457.83 |
Creative Medical Technology Holdings Inc - Net Assets Trend (2006–2025)
This chart illustrates how Creative Medical Technology Holdings Inc's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Creative Medical Technology Holdings Inc to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Creative Medical Technology Holdings Inc (2006–2025)
The table below shows the annual net assets of Creative Medical Technology Holdings Inc from 2006 to 2025. For live valuation and market cap data, see CELZ company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $7.52 Million | +18.66% |
| 2024-12-31 | $6.34 Million | -38.69% |
| 2023-12-31 | $10.34 Million | -34.80% |
| 2022-12-31 | $15.86 Million | +55.27% |
| 2021-12-31 | $10.22 Million | +125.67% |
| 2020-12-31 | $-39.80 Million | -393.13% |
| 2019-12-31 | $-8.07 Million | -102.06% |
| 2018-12-31 | $-3.99 Million | -78.64% |
| 2017-12-31 | $-2.24 Million | -1317.17% |
| 2016-12-31 | $-157.79K | +14.15% |
| 2015-12-31 | $-183.80K | -20.10% |
| 2014-12-31 | $-153.04K | -22.40% |
| 2013-12-31 | $-125.03K | -27.91% |
| 2012-12-31 | $-97.75K | -35.45% |
| 2011-12-31 | $-72.16K | -50.00% |
| 2010-12-31 | $-48.11K | -55.93% |
| 2009-12-31 | $-30.85K | -4175.69% |
| 2008-12-31 | $757.00 | -97.13% |
| 2007-12-31 | $26.35K | +26.12% |
| 2006-12-31 | $20.89K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Creative Medical Technology Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7047756300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.14K | 0.04% |
| Other Components | $78.10 Million | 1039.28% |
| Total Equity | $7.51 Million | 100.00% |
Creative Medical Technology Holdings Inc Competitors by Market Cap
The table below lists competitors of Creative Medical Technology Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Airway
WAR:AWM
|
$8.28 Million |
|
Renoworks Software Inc
V:RW
|
$8.28 Million |
|
Dr. Martens PLC
LSE:DOCS
|
$8.29 Million |
|
Oxbridge Re Holdings Ltd
NASDAQ:OXBR
|
$8.30 Million |
|
Trinseo SA
NYSE:TSE
|
$8.28 Million |
|
Petro-Victory Energy Corp
V:VRY
|
$8.28 Million |
|
SPOTLIGHT GROUP AB O.N.
F:7T7
|
$8.27 Million |
|
Morien Resources Corp
V:MOX
|
$8.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Creative Medical Technology Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,341,499 to 7,514,645, a change of 1,173,146 (18.5%).
- Net loss of 5,995,008 reduced equity.
- Share repurchases of 10,000 reduced equity.
- New share issuances of 7,174,669 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.00 Million | -79.78% |
| Share Repurchases | $10.00K | -0.13% |
| Share Issuances | $7.17 Million | +95.48% |
| Other Changes | $3.48K | +0.05% |
| Total Change | $- | 18.50% |
Book Value vs Market Value Analysis
This analysis compares Creative Medical Technology Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.71x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.71x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | $870.50 | $2.24 | x |
| 2007-12-31 | $1097.83 | $2.24 | x |
| 2008-12-31 | $31.54 | $2.24 | x |
| 2009-12-31 | $-1285.54 | $2.24 | x |
| 2010-12-31 | $-2004.54 | $2.24 | x |
| 2011-12-31 | $-3006.83 | $2.24 | x |
| 2012-12-31 | $-4072.88 | $2.24 | x |
| 2013-12-31 | $-5209.63 | $2.24 | x |
| 2014-12-31 | $-6376.79 | $2.24 | x |
| 2015-12-31 | $-7658.50 | $2.24 | x |
| 2016-12-31 | $-1127.08 | $2.24 | x |
| 2017-12-31 | $-14615.51 | $2.24 | x |
| 2018-12-31 | $-3320.56 | $2.24 | x |
| 2019-12-31 | $-3903.05 | $2.24 | x |
| 2020-12-31 | $-686.90 | $2.24 | x |
| 2021-12-31 | $31.45 | $2.24 | x |
| 2022-12-31 | $14.51 | $2.24 | x |
| 2023-12-31 | $7.35 | $2.24 | x |
| 2024-12-31 | $4.28 | $2.24 | x |
| 2025-12-31 | $3.15 | $2.24 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Creative Medical Technology Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -79.78%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -99916.80%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.04x
- Recent ROE (-79.78%) is above the historical average (-353.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 6.57% | 0.00% | 0.00x | 1.40x | $-717.20 |
| 2007 | -36.22% | 0.00% | 0.00x | 1.35x | $-12.18K |
| 2008 | -6953.24% | 0.00% | 0.00x | 1.98x | $-52.71K |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-28.52K |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.45K |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.84K |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.81K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.78K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.71K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.38K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-750.29K |
| 2017 | 0.00% | -55398.08% | 0.02x | 0.00x | $-2.44 Million |
| 2018 | 0.00% | -10977.21% | 0.26x | 0.00x | $-13.26 Million |
| 2019 | 0.00% | -5126.09% | 0.31x | 0.00x | $-7.68 Million |
| 2020 | 0.00% | -22082.21% | 0.23x | 0.00x | $-32.34 Million |
| 2021 | 188.02% | 21892.75% | 0.01x | 1.10x | $18.19 Million |
| 2022 | -63.94% | -11449.26% | 0.00x | 1.21x | $-11.73 Million |
| 2023 | -51.11% | -58739.71% | 0.00x | 1.04x | $-6.32 Million |
| 2024 | -86.63% | -49940.74% | 0.00x | 1.05x | $-6.13 Million |
| 2025 | -79.78% | -99916.80% | 0.00x | 1.04x | $-6.75 Million |
Industry Comparison
This section compares Creative Medical Technology Holdings Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Creative Medical Technology Holdings Inc (CELZ) | $6.13 Million | 6.57% | 0.05x | $8.28 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Creative Medical Technology Holdings Inc
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DD… Read more